Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 2.538 2.34% 0.06
CLRB closed up 2.34 percent on Friday, January 17, 2020, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical CLRB trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
MACD Bearish Signal Line Cross Bearish 2.34%
Bearish Engulfing Bearish 1.12%
Jack-in-the-Box Bullish Bullish Swing Setup 1.12%
Upper Bollinger Band Walk Strength 1.12%
Upper Bollinger Band Touch Strength 1.12%
Expansion Breakout Bullish Swing Setup -5.30%
Pocket Pivot Bullish Swing Setup -5.30%
Volume Surge Other -5.30%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Medicine Cancer Clinical Medicine Imaging Oncology Stem Cells Chemotherapy Radiation Occupational Safety And Health Antineoplastic Drugs Radiation Therapy Glioblastoma Targeted Therapy Tomography Solid Tumor Advanced Solid Tumors Ros1

Is CLRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.75
52 Week Low 1.04
Average Volume 121,473
200-Day Moving Average 2.08
50-Day Moving Average 1.97
20-Day Moving Average 2.38
10-Day Moving Average 2.50
Average True Range 0.18
ADX 45.77
+DI 24.42
-DI 12.64
Chandelier Exit (Long, 3 ATRs ) 2.21
Chandelier Exit (Short, 3 ATRs ) 2.54
Upper Bollinger Band 2.69
Lower Bollinger Band 2.07
Percent B (%b) 0.76
BandWidth 26.00
MACD Line 0.15
MACD Signal Line 0.16
MACD Histogram -0.0081
Fundamentals Value
Market Cap 35.33 Million
Num Shares 13.9 Million
EPS -1.13
Price-to-Earnings (P/E) Ratio -2.25
Price-to-Sales 0.00
Price-to-Book 1.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.71
Resistance 3 (R3) 2.70 2.63 2.68
Resistance 2 (R2) 2.63 2.58 2.63 2.67
Resistance 1 (R1) 2.58 2.55 2.60 2.60 2.66
Pivot Point 2.51 2.51 2.52 2.52 2.51
Support 1 (S1) 2.47 2.47 2.49 2.48 2.41
Support 2 (S2) 2.40 2.44 2.40 2.40
Support 3 (S3) 2.35 2.40 2.39
Support 4 (S4) 2.37